Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

Hepatology International

Volumn 4, Issue 1, 2010, Pages 386-395

  Ahn, Sang Hoon ^a   Chan, Henry L Y ^b   Chen, Pei Jer ^c   Cheng, Jun ^d   Goenka, Mahesh K ^e   Hou, Jinlin ^f   Lim, Seng Gee ^g   Omata, Masao ^h   Piratvisuth, Teerha ⁱ   Xie, Qing ^j   Yim, Hyung Joon ^k   Yuen, Man Fung ^l  

^a Yonsei University College of Medicine   (South Korea)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Apollo Gleneagles Hospital   (India)

^f SOUTHERN MEDICAL UNIVERSITY   (China)

^g NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^j SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^k Korea University College of Medicine   (South Korea)

^l UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

ALT; Chronic hepatitis B (CHB); HBV DNA; Hepatitis B virus (HBV); Interferon alfa; Nucleoside nucleotide analog

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLEVUDINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; ELASTOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER HISTOLOGY; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETREATMENT; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 84984538817     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9163-9     Document Type: Review

References (98)

1. YF Liaw N Leung JH Kao T Piratvisuth E Gane KH Han, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008-9080-3 19669255
2. ASF Lok BJ McMahon 2007 AASLD practice guidelines. Chronic hepatitis B Hepatology 45 507 539 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D 17256718 (Pubitemid 46374607)
3. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001 1:STN:280:DC%2BD1M%2FntlOjtA%3D%3D 19054588
4. EB Keeffe DT Dieterich SHB Han IM Jacobson P Martin ER Schiff, et al. 2008 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 6 1315 1341 10.1016/j.cgh.2008.08.021 1:CAS:528:DC%2BD1MXhtFSlurk%3D 18845489
5. MJ Tong C Hsien L Hsu HE Sun LM Blatt 2008 Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history in the United States Hepatology 48 1070 1078 10.1002/hep.22476 18688879
6. MF Yuen Y Tanaka DYT Fong J Fung DKH Wong JCH Yuen, et al. 2009 Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 80 88 10.1016/j.jhep.2008.07.023 18977053
7. CL Lai MF Yuen 2007 The natural history of chronic hepatitis B and its treatment: a critical evaluation of standard treatment criteria and end points Ann Intern Med 147 58 61 17606962
8. International Agency for Research on Cancer. Hepatitis viruses. In: IARC monographs on the evaluation of carcinogenic risks to humans. Vol 59. Lyon (France): WHO Press; 1995. 8
9. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. In: IARC CancerBase No. 5 Version 2.0 (ed). Lyon (France): IARC Press; 2004
10. World Health Organization. Global burden of cancer. In: Cancer. Geneva; 2009
11. KH Han SH Ahn 2005 How to predict HCC development in patients with chronic B viral liver disease? Intervirology 48 23 28 10.1159/000082091 15785086 (Pubitemid 40529207)
12. F Zoulim R Perrillo 2008 Hepatitis B: reflections on the current approach to antiviral therapy J Hepatol 48 Suppl 1 S2 S19 10.1016/j.jhep.2008.01.011 1:CAS:528:DC%2BD1cXjtlelsL8%3D 18304680
13. HL Chan CH Tse F Mo J Koh VWS Wong GLH Wong, et al. 2008 High viral load and hepatitis B virus subgenotype Ce are associated with an increased risk of hepatocellular carcinoma J Clin Oncol 26 177 182 10.1200/JCO.2007.13.2043 1:CAS:528:DC%2BD1cXitVWitr8%3D 18182659
14. G Chen W Lin F Shen UH Iloeje WT London AA Evans 2006 Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 1797 1803 10.1111/j.1572-0241.2006. 00647.x 16817842 (Pubitemid 44166589)
15. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218 (Pubitemid 43042691)
16. MF Yuen HJ Yuan DKH Wong AOO Chan BCY Wong KC Lai, et al. 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut 54 1610 1614 10.1136/gut.2005.065136 15871997 (Pubitemid 41531781)
17. M Sherman 2005 Predicting survival in hepatitis B Gut 54 1521 1523 10.1136/gut.2005.071332 1:STN:280:DC%2BD2MrltVeiug%3D%3D 16227355 (Pubitemid 41531763)
18. MF Yuen Y Tanaka N Shinkai RT Poon DYK But DYT Fong, et al. 2008 Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels Gut 57 98 102 10.1136/gut.2007.119859 1:CAS:528:DC%2BD1cXitVKqt78%3D 17483190
19. HL Chan AY Hui ML Wong AML Tse LCT Hung VWS Wong, et al. 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 1494 1498 10.1136/gut.2003.033324 15361502 (Pubitemid 39265273)
20. HI Yang SH Yeh PJ Chen UH Iloeje CL Jen J Su, et al. 2008 Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma J Natl Cancer Inst 100 1134 1143 10.1093/jnci/djn243 1:CAS:528:DC%2BD1cXhtFKrsb7P 18695135
21. HL Chan SK Tsui CH Tse EYT Ng TCC Au L Yuen, et al. 2005 Epidemiological and virological characteristics of two subgroups of genotype C hepatitis C virus J Infect Dis 191 2022 2032 10.1086/430324 1:CAS:528:DC%2BD2MXlvFShsr4%3D 15897987 (Pubitemid 40800572)
22. JH Kao 2007 Role of viral factors in the natural course and therapy of chronic hepatitis B Hepatol Int 1 415 430 10.1007/s12072-007-9033-2 19669337
23. MF Yuen DK Wong E Sablon HJ Yuan SM Sum CK Hui 2003 Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine Antivir Ther 8 531 534 1:CAS:528:DC%2BD2cXivVSqurg%3D 14760886
24. HL Chan ML Wong AY Hui AM Chim AM Tse LC Hung 2003 Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment World J Gastroenterol 9 2695 2697 1:CAS:528:DC%2BD2cXmt1CmtQ%3D%3D 14669315
25. ZL Fang CA Sabin BQ Dong SC Wei QY Chen KX Fang, et al. 2008 Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study J Gen Virol 89 2882 2890 10.1099/vir.0.2008/ 002824-0 1:CAS:528:DC%2BD1cXhtlOqtL%2FM 18931087
26. Y Tanaka M Mukaide E Orito MF Yuen K Ito F Kurbanov, et al. 2006 Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma J Hepatol 45 646 653 10.1016/j.jhep.2006.06.018 1:CAS:528:DC%2BD28XhtVWqtr%2FJ 16935384 (Pubitemid 44466666)
27. MK Osborn ASF Lok 2006 Antiviral options for the treatment of chronic hepatitis B J Antimicrob Chemother 57 1030 1034 10.1093/jac/dkl123 1:CAS:528:DC%2BD28XmsFyktr0%3D 16595637 (Pubitemid 44644402)
28. PSY Tsang H Trinh RT Garcia JT Phan BHA Nghiem H Nguyen, et al. 2008 Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels Clin Gastroenterol Hepatol 6 569 574 10.1016/j.cgh.2008.02.037 18455697
29. JY Park YN Park DY Kim YH Paik KS Lee BS Moon, et al. 2008 High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels J Viral Hepat 15 615 621 10.1111/j.1365-2893.2008.00989.x
30. BK Park YN Park SH Ahn KS Lee CY Chon YM Moon, et al. 2007 Long-term outcome of chronic hepatitis B based on histological grade and stage J Gastroenterol Hepatol 22 383 388 10.1111/j.1440-1746.2007.04857.x 1:CAS:528:DC%2BD2sXksFKntrk%3D 17295771 (Pubitemid 46238769)
31. DI Tai SM Lin IS Sheen CM Chu DY Lin YF Liaw 2009 Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time Hepatology 49 1859 1867 10.1002/hep.22878 1:CAS:528:DC%2BD1MXotVCmtLY%3D 19378345
32. Gui H, Xie Q, Wang H, Lin Z, Cai W, Zhou X, et al. Predictors of significant histological findings in chronic hepatitis B patients with persistently normal ALT levels. In: Proceedings of the American Association for the Study of Liver Disease (AASLD); 2007; Boston, MA. Hepatology 2007;46 Suppl 1:653A
33. GL Wong VW Wong PC Choi AW Chan AM Chim KK Yiu, et al. 2008 Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography Am J Gastroenterol 103 3071 3081 10.1111/j.1572-0241.2008.02157.x 19086958
34. GL Wong VW Wong PC Choi AW Chan AM Chim KK Yiu, et al. 2009 Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B Clin Gastroenterol Hepatol 7 227 233 10.1016/j.cgh.2008.10. 023 19121647
35. J Fung CL Lai D But D Wong TK Cheung MF Yuen 2008 Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management Am J Gastroenterol 103 1421 1426 10.1111/j.1572-0241.2007.01751.x 18422821
36. HC Kim CM Nam SH Jee KH Han DK Oh I Suh 2004 Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study BMJ 328 983 10.1136/bmj.38050.593634.63 1:CAS:528:DC%2BD2cXksFOmtbs%3D 15028636
37. R Kariv M Leshno A Beth-Or H Strul L Blendis E Kokia, et al. 2006 Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study Liver Int 26 445 450 10.1111/j.1478-3231.2006.01197.x 1:CAS:528:DC%2BD28XlsVKgtrg%3D 16629648
38. A Piton T Poynard F Imbert-Bismut L Khalil J Delattre E Pelissier, et al. 1998 Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group Hepatology 27 1213 1219 10.1002/hep.510270505 1:CAS:528:DyaK1cXjtVSjsbk%3D 9581673 (Pubitemid 28227846)
39. D Prati E Taioli A Zanella E Della Torre S Butelli E Del Vecchio, et al. 2002 Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med 137 1 10 1:CAS:528:DC%2BD38Xls1entbc%3D 12093239
40. YS Hsu RN Chien CT Yeh IS Sheen HY Chiou CM Chu, et al. 2002 Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 1522 1527 10.1053/jhep.2002.33638 12029639
41. M Lai BJ Hyatt I Nasser M Curry NH Afdhal 2007 The clinical significance of persistently normal ALT in chronic hepatitis B infection J Hepatol 47 760 767 10.1016/j.jhep.2007.07.022 1:CAS:528:DC%2BD2sXht12ns7bI 17928090 (Pubitemid 350051121)
42. ASF Lok BJ McMahon 2001 AASLD practice guidelines. Chronic hepatitis B Hepatology 34 1225 1241 10.1053/jhep.2001.29401 1:STN:280:DC%2BD3MnosV2qtw%3D%3D 11732013 (Pubitemid 33096596)
43. Papatheodoridis G, Manesis E, Manolakopoulos S, Goulis J, Chrysanthos N, Bilalis A. HBeAg-negative chronic hepatitis B (CHBe-) in chronic HBV patients with serum HBV-DNA levels below 2000 IU/mL. In: Proceedings of the European Association for the Study of the Liver (EASL); 2007; Barcelona, Spain. J Hepatol 2007;46: Suppl 1;S183
44. HL Chan ML Wong AY Hui LC Hung FK Chan JJ Sung 2003 Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B J Clin Microbiol 41 4793 4795 10.1128/JCM.41.10.4793-4795. 2003 14532223 (Pubitemid 37259797)
45. CJ Chu M Hussain ASF Lok 2002 Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 36 1408 1415 1:CAS:528:DC%2BD38Xps1ylurs%3D 12447866
46. HJ Yuan MF Yuen DKH Wong E Sablon CL Lai 2005 The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B J Viral Hepat 12 373 379 10.1111/j.1365-2893.2005.00603.x 15985007 (Pubitemid 40961476)
47. Iloeje UH, Yang HI, Su J. HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L. HBV study. In: Proceedings of the American Association for the Study of Liver Disease (AASLD); 2007; Boston, MA. Hepatology 2007;46 Suppl 1:640A
48. HL Chan 2009 Revisiting the treatment recommendations for chronic hepatitis B Hepatology 49 700 10.1002/hep.22714 19177582
49. P Bedossa D Dargere V Paradis 2003 Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 1449 1457 14647056
50. M Omata 2004 Regression of liver fibrosis in patients treated by interferon Intern Med 43 887 888 10.2169/internalmedicine.43.887 15575231 (Pubitemid 39534785)
51. KH Han KT Yoon 2008 New diagnostic methods for liver fibrosis and cirrhosis Intervirology 51 Suppl 1 11 16 10.1159/000122594 18544943
52. M Pinzani F Vizzutti U Arena F Marra 2008 Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography Nat Clin Pract Gastroenterol Hepatol 5 95 106 10.1038/ncpgasthep1025 1:CAS:528: DC%2BD1cXhs1Ojtb8%3D 18253138
53. CT Wai CL Cheng A Wee YY Dan E Chan W Chua, et al. 2006 Non-invasive models for predicting histology in patients with chronic hepatitis B Liver Int 26 666 672 10.1111/j.1478-3231.2006.01287.x 16842322 (Pubitemid 43983883)
54. PE Chang HF Lui YP Chau KH Lim WM Yap CK Tan, et al. 2008 Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index Aliment Pharmacol Ther 28 51 61 1:CAS:528:DC%2BD1cXovFelsbk%3D 18410556
55. AY Hui HL Chan VW Wong CT Liew AM Chim FK Chan, et al. 2005 Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model Am J Gastroenterol 100 616 623 10.1111/j.1572-0241.2005.41289.x 15743360 (Pubitemid 40487561)
56. HS Kim JK Kim YN Park SM Myung MS Pang KT Yoon, et al. 2007 Non-invasive assessment of liver fibrosis by measuring the liver stiffness and biochemical markers in chronic hepatitis B patients Korean J Med 72 459 469 1:CAS:528:DC%2BD2sXmtlartr4%3D
57. SU Kim SH Ahn JY Park W Kang DY Kim YN Park, et al. 2009 Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis J Clin Gastroenterol 43 267 271 10.1097/MCG. 0b013e31816f212e 18987556
58. M Friedrich-Rust MF Ong S Martens C Sarrazin J Bojunga S Zeuzem, et al. 2008 Performance of transient elastography for the staging of liver fibrosis: a meta-analysis Gastroenterology 134 960 974 10.1053/j.gastro.2008.01.034 18395077
59. JA Talwalkar DM Kurtz SJ Schoenleber CP West VM Montori 2007 Ultrasound-based transient elastography for the detection of hepatic fibrosis: systemic review and meta-analysis Clin Gastroenterol Hepatol 5 1214 1220 10.1016/j.cgh.2007.07.020 17916549 (Pubitemid 47488974)
60. P Marcellin M Ziol P Bedossa C Douvin R Poupon V de Lédinghen, et al. 2009 Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B Liver Int 29 242 247 10.1111/j.1478-3231.2008. 01947.x 18637064
61. HL Chan GL Wong PC Choi AW Chan AM Chim KK Yiu, et al. 2009 Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (FibroScan) for liver fibrosis in chronic hepatitis B J Viral Hepat 16 36 44 10.1111/j.1365-2893.2008.01037.x 18673426
62. DY Kim SU Kim SH Ahn JY Park JM Lee YN Park, et al. 2008 Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B Dig Dis Sci 54 1758 1763 10.1007/s10620-008-0541-2 19005758
63. A Kettaneh P Marcellin C Douvin R Poupon M Ziol M Beaugrand, et al. 2007 Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients J Hepatol 46 628 634 10.1016/j.jhep.2006.11.010 17258346 (Pubitemid 46420381)
64. J Foucher L Castéra PH Bernard X Adhoute D Laharie J Bertet, et al. 2006 Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations Eur J Gastroenterol Hepatol 18 411 412 10.1097/00042737-200604000-00015 16538113
65. B Coco F Oliveri AM Maina P Ciccorossi R Sacco P Colombatto, et al. 2007 Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases J Viral Hepat 14 360 369 10.1111/j.1365-2893. 2006.00811.x 1:STN:280:DC%2BD2s3jtFamtQ%3D%3D 17439526 (Pubitemid 46587854)
66. SM Domchek A Eisen C Calzone J Stopfer A Blackwood BL Weber 2003 Application of breast cancer risk prediction models in clinical practice J Clin Oncol 21 593 601 10.1200/JCO.2003.07.007 12586794 (Pubitemid 46621891)
67. G L'Italien I Ford J Norrie P LaPuerta J Ehreth J Jackson, et al. 2000 The cardiovascular event reduction tool (CERT): a simplified cardiac risk prediction model developed from the West of Scotland Coronary Primary Prevention Study (WOSCOPS) Am J Cardiol 85 720 724 10.1016/S0002-9149(99)00847-4 12000046 (Pubitemid 30133392)
68. CJ Chen UH Iloeje HI Yang 2007 Long-term outcomes in hepatitis B: the REVEAL-HBV study Clin Liver Dis 11 797 816 10.1016/j.cld.2007.08.005 17981229 (Pubitemid 350019025)
69. Chen CJ, Yang HI, Iloeje UH, Jen CL, You SL, Sherman M, et al. HBV DNA & genotype predict HCC. In: Levin J, editor. Digestive Disease Week 2007. Washington (DC); 2007
70. J Fung CL Lai MF Yuen 2008 New paradigms for the treatment of chronic hepatitis B J Gastroenterol Hepatol 23 1182 1192 10.1111/j.1440-1746.2008.05400. x 1:CAS:528:DC%2BD1cXhtFensbnN 18637060
71. RG Gish ASF Lok TT Chang RA de Man A Gadano J Sollano, et al. 2007 Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 133 1437 1444 10.1053/j.gastro.2007.08.025 1:CAS:528:DC%2BD2sXhsVGqtr%2FI 17983800 (Pubitemid 350029745)
72. P Marcellin EJ Heathcote M Buti E Gane RA de Man Z Krastev, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 10.1056/NEJMoa0802878 1:CAS:528:DC%2BD1cXhsVCrurjL 19052126
73. CT Yeh CW Hsu YC Chen YF Liaw 2009 Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression J Clin Virol 45 114 118 10.1016/j.jcv.2009.04.006 1:CAS:528:DC%2BD1MXms1ygtrs%3D 19451024
74. HI Yang SN Lu YF Liaw SL You CA Sun LY Wang, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174 10.1056/NEJMoa013215 1:CAS:528:DC%2BD38Xlt12jsLw%3D 12124405
75. YF Liaw DI Tai CM Chu TJ Chen 1988 The development of cirrhosis in patients with chronic type B hepatitis: a prospective study Hepatology 8 493 496 10.1002/hep.1840080310 1:STN:280:DyaL1c3is1CmtQ%3D%3D 3371868
76. Lim SG, Oo AM, Wasser S. Treatment-induced HBeAg seroconversion is a poor therapeutic endpoint. In: Proceedings of the American Association for the Study of Liver Disease (AASLD); 2007; Boston, MA. Hepatology 2007;46 Suppl 1:653A
77. RN Chien CT Yeh SL Tsai CM Chu YF Liaw 2003 Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 1267 1273 10.1053/jhep.2003.50458 1:CAS:528:DC%2BD3sXpsVOnt7w%3D 14578866 (Pubitemid 37314836)
78. BC Song DJ Suh HC Lee YH Chung YS Lee 2000 Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 803 806 10.1053/jhep.2000.16665 1:CAS:528:DC%2BD3cXnslemsbg%3D 11003626
79. SK Fung F Wong M Hussain ASF Lok 2004 Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B J Viral Hepat 11 432 438 10.1111/j.1365-2893.2004.00556.x 1:STN:280:DC%2BD2cvltVOgtA%3D%3D 15357648 (Pubitemid 39336224)
80. HL Chan H Wang J Niu AM Chim JJ Sung 2007 Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial Antivir Ther 12 345 353 1:CAS:528:DC%2BD2sXntFOrsbc%3D 17591024
81. RN Chien YF Liaw 2006 Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan Antivir Ther 11 947 952 1:CAS:528:DC%2BD28Xhtlajs7vI 17302259
82. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto, et al. 2005 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2673 2681 10.1056/NEJMoa042957 1:CAS:528:DC%2BD2MXls1Sksbc%3D 15987916 (Pubitemid 41007822)
83. P Marcellin GKK Lau F Bonino P Farci S Hadziyannis R Jin, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D 15371578 (Pubitemid 39296307)
84. MF Yuen DKH Wong E Sablon E Tse IOL Ng HJ Yuan, et al. 2004 HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects Hepatology 39 1694 1701 10.1002/hep.20240 15185311 (Pubitemid 38702671)
85. SH Ahn YN Park JY Park HY Chang JM Lee JE Shin, et al. 2005 Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance J Hepatol 42 188 194 10.1016/j.jhep.2004.10.026 1:CAS:528:DC%2BD2MXmvFSqtQ%3D%3D 15664243 (Pubitemid 40143464)
86. MF Yuen DKH Wong J Fung P Ip D But I Hung, et al. 2008 HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 1192 1199 10.1053/j.gastro.2008.07.008 1:CAS:528:DC%2BD1cXht12lurrP 18722377
87. CM Chu YF Liaw 2007 HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up Hepatology 45 1187 1192 10.1002/hep.21612 17465003 (Pubitemid 46775781)
88. TT Chang CL Lai RN Chien R Guan SG Lim CM Lee, et al. 2004 Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 1276 1282 10.1111/j.1440-1746.2004.03428.x 1:CAS:528:DC%2BD2cXhtVKnt7vJ 15482535 (Pubitemid 39481762)
89. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1741 1743 10.1053/j.gastro.2006.09.020
90. YS Kim JY Jang SH Eun YK Cheon YS Kim JH Moon, et al. 2006 Detection of intrahepatic HBV DNA in HBsAg-negative liver diseases Korean J Hepatol 12 201 208 16804345
91. S Momosaki Y Nakashima M Kojiro E Tabor 2005 HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma J Viral Hepat 12 325 329 10.1111/j.1365-2893.2005.00586.x 1:STN:280: DC%2BD2M3hslWguw%3D%3D 15850475 (Pubitemid 40638042)
92. RD Fleischer ASF Lok 2009 Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 787 791 10.1016/j.jhep.2009.06.011 1:CAS:528:DC%2BD1MXhtFagt7%2FJ 19665816
93. YF Liaw E Gane N Leung S Zeuzem Y Wang CL Lai, et al. 2009 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 486 495 10.1053/j.gastro.2008.10.026 1:CAS:528:DC%2BD1MXislOhtLs%3D 19027013
94. P Marcellin T Chang SG Lim MJ Tong W Sievert ML Shiffman, et al. 2003 Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive hepatitis B N Engl J Med 348 808 816 10.1056/NEJMoa020681 1:CAS:528:DC%2BD3sXhsFKisrc%3D 12606735 (Pubitemid 36245757)
95. JW Shin NH Park JH Park JH Park ID Jeong SJ Bang, et al. 2005 Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B J Viral Hepat 12 393 397 10.1111/j.1365-2893.2005.00606.x 1:STN:280:DC%2BD2MzjsV2itw%3D%3D 15985010 (Pubitemid 40961479)
96. Shouval D, Lai CL, Chang TT, Tan CK. Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901. In: Proceedings of the American Association for the Study of Liver Diseases (AASLD); 2008; San Francisco, CA. Hepatology 2008;48 Suppl 1;722A
97. RG Gish DT Lau P Schmid R Perrillo 2007 A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B Am J Gastroenterol 102 2718 2723 10.1111/j.1572-0241.2007. 01449.x 1:CAS:528:DC%2BD1cXkvVCksw%3D%3D 17662102 (Pubitemid 350179320)
98. HL Chan VW Wong AM Tse CH Tse AM Chim HY Chan, et al. 2007 Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 1462 1468 10.1016/j.cgh.2007.09.005 1:CAS:528:DC%2BD1cXlslSqsg%3D%3D 18054753 (Pubitemid 350181604)